Skip to content
ChickenStockChickenStock
ResearchNAMS
Newamsterdam Pharma logo

Newamsterdam Pharma (NAMS) stock

NASDAQ

$20.14+0.85%(+0.17)

As of the Nov 13, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-11.85x

Net loss — not comparable

P/B

3.83x

P/S

—

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue decreased 34.5% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

12 SEC filings
  • Kastelein Johannes Jacob PieterChief Scientific Officer · Sep 30, 2026Open-market sale50,246 shares · $1.3M
    Avg. price $25.0369,302 shares held after
  • Kastelein Johannes Jacob PieterChief Scientific Officer · Sep 30, 2026Option exercise50,246 shares
    119,548 shares held after
  • Davidson Michael H.Chief Executive Officer · Sep 14, 2026Open-market purchase10,000 shares · $227K
    Avg. price $22.65792,923 shares held after
  • Smither John WDirector · Sep 4, 2026Open-market sale1,600 shares · $41K
    Avg. price $25.328,760 shares held after
  • Gunning Robert WilliamVice President, Controller · Sep 1, 2026Grant or award3,200 shares · $0
    Avg. price $03,200 shares held after
  • Kastelein Johannes Jacob PieterChief Scientific Officer · Aug 24, 2026Open-market sale125,000 shares · $3.4M
    Avg. price $26.9169,302 shares held after
  • Kastelein Johannes Jacob PieterChief Scientific Officer · Aug 24, 2026Option exercise125,000 shares
    194,302 shares held after
  • Kooij Louise FrederikaChief Accounting Officer · Jul 20, 2026Open-market sale105,000 shares · $3.2M
    Avg. price $30.3396
    Show 3 price lots
    • 70,200 shares × $29.96$2.1M
    • 31,885 shares × $31.05$990K
    • 2,915 shares × $31.71$92K
  • Kooij Louise FrederikaChief Accounting Officer · Jul 20, 2026Option exercise105,000 shares · $1.2M
    Avg. price $11.3438
    Show 2 price lots
    • 80,000 shares × $11.17$894K
    • 25,000 shares × $11.9$298K

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Newamsterdam Pharma (NAMS) stock information

NASDAQ

Newamsterdam Pharma (NAMS) is listed on NASDAQ. Its market capitalization is about $2.4B. On trailing-twelve-month earnings the P/E ratio is -11.85, and the P/B ratio is 3.83. Return on equity is -32.3%. These figures are computed in-house from official filings and are reference information only.

Newamsterdam Pharma — frequently asked questions

What is the P/E ratio of Newamsterdam Pharma (NAMS)?
On a trailing-twelve-month basis, NAMS trades at a P/E ratio of -11.85. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Newamsterdam Pharma?
NAMS has a market capitalization of about $2.4B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.